ASweetLife Team, Author at ASweetLife

Exenatide Once Weekly Provided Superior Glucose Control Compared to Byetta in Tests

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to Byetta (exenatide injection taken twice daily), in patients with type 2 diabetes...

Array BioPharma and Amgen Partner in Type 2 Diabetes

Array BioPharma Inc. and Amgen Inc. announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with type 2 diabetes. Amgen will pay $60 million up-front with additional potential milestones and royalties payments to Array...

FDA Approves Diamyd Vaccine Study In Children As Young As 3

Diamyd Medical, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, reports today that the US FDA has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America...

First Treatment For Diabetic Related Eye Disease May Soon Be Available

According to a JDRF press release great progress has been made towards finding a treatment for diabetes-related eye disease. Novartis Pharmaceuticals, based in Switzerland, announced that the drug Lucentis has been submitted to the European Union's regulatory agency, European Medicines Agency, for approval for the treatment of diabetic macular edema...

Diabetes UK to Fund New Diabetes Research

Diabetes UK announced that it would be dedicating almost £750,000 ($1,200,000) to four new research projects looking to understand the causes of diabetes, help with its day-to-day management and protect against its complications. "We are delighted to be supporting this new research and hope that it will bring benefit and improvements for people living...

Eli Lilly Announces The First 300-Unit Vial of Insulin

Eli Lilly and Company announced the availability of a smaller vial of insulin containing 3 mL (300 units), the first such vial in the United States. A typical vial of insulin contains 10 mL, or 1,000 "units" of insulin. Lilly developed this new smaller vial for use in hospitals based on feedback regarding the average duration of patient hospital stays.

EyeSmart EyeCommitted

Diabetic retinopathy is the leading cause of new cases of legal blindness in working-age Americans, and more than half of all people living with diabetes do not get the recommended annual dilated eye exams.

Novo Nordisk Starts Phase 1 Trial With Oral Insulin

Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes...

Senate Passes Women’s Health Amendment

The US Senate approved an amendment, put forward by Senator Barbara Mikulski, Democrat of Maryland, that would require insurance companies to offer free mammograms and other preventive services including annual diabetes screening...

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines

The National Institute of Health (NIH) announced the approval of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009. Children's Hospital Boston developed 11 of the approved lines and Rockefeller University in New York City developed two of the approved lines....